| Drug Name |
Cannabidiol |
| Drug ID |
BADD_D02468 |
| Description |
Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses [A32477, A32469]. CBD's exact place within medical practice is still currently hotly debated, however as the body of evidence grows and legislation changes to reflect its wide-spread use, public and medical opinion have changed significantly with regards to its usefulness in a number of medical conditions ranging from anxiety to epilepsy. |
| Indications and Usage |
When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:
1) as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy [L886];
Due to the need for confirmatory studies to verify the clinical benefit coupled with the promising nature of the clinical evidence, Sativex was also given a Notice of Compliance with Conditions (NOC/c) by Health Canada for the following indications:
1) as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis;
2) as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain [L886]. |
| Marketing Status |
approved; investigational |
| ATC Code |
N03AX24 |
| DrugBank ID |
DB09061
|
| KEGG ID |
D10915
|
| MeSH ID |
D002185
|
| PubChem ID |
644019
|
| TTD Drug ID |
D0O1UZ
|
| NDC Product Code |
68108-0881; 73548-2155; 51634-2155; 48251-0300; 73435-015; 70127-100; 82876-001; 82876-283; 57821-006 |
| UNII |
19GBJ60SN5
|
| Synonyms |
Cannabidiol | 1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)- | Epidiolex |
